Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell

被引:17
作者
Luo, Xian-Run [1 ,2 ]
Li, Jian-Sheng [1 ]
Niu, Ying [1 ]
Miao, Li [2 ]
机构
[1] ZhengZhou Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhengzhou 450052, Henan, Peoples R China
[2] Henan Prov Corps Hosp, Zhengzhou 450052, Peoples R China
关键词
Suicide gene; Survivin promoter; Gastric carcinoma; Gene therapy; ANTI-APOPTOSIS GENE; IN-VITRO; CYTOSINE DEAMINASE; THERAPY; EXPRESSION; CARCINOMA; GROWTH; ADENOCARCINOMA; CHEMOTHERAPY; TOXICITY;
D O I
10.1007/s11033-010-0218-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Suicide genes such as cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) encode products that convert nontoxic substances (prodrugs) into toxic metabolites. Studies in recent years indicated that survivin(sur) expression was associated with the biological behaviors of gastric carcinoma. In the present study, targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell were investigated, the recombinant pSCT vector containing CD and TK genes driven by sur promoter was constructed and transfected into SGC-7901 cells. After adding the CCV and 5-FC, the effects of double suicide genes on cell growth, cell cycle and proliferation were determined by MTT assay and flow cytometry (FCM). The results showed that sur promoter could specifically drive the expression of double CD/TK gene in SGC-7901 cells, whereas not in the normal GES-1 cell. After using CCV and 5-FC, the growth of SGC-7901 cells was inhibited. G1 phase proportion was significantly higher in SGC-7901 cells transfected with double suicide genes than the untransfected cells. These results suggest that CD and TK double suicide genes driven by sur promoter could provide a new approach for enhancing selective suicide gene therapy of CD/5-FC for the treatment of advanced gastric carcinoma.
引用
收藏
页码:1201 / 1207
页数:7
相关论文
共 40 条
[1]
Adida C, 1998, AM J PATHOL, V152, P43
[2]
Targeted therapy by disabling crossroad signaling networks:: the survivin paradigm [J].
Altieri, DC .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :478-482
[3]
Validating survivin as a cancer therapeutic target [J].
Altieri, DC .
NATURE REVIEWS CANCER, 2003, 3 (01) :46-54
[4]
Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm [J].
Altieri, DC .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 92 (04) :656-663
[5]
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[6]
Both GW, 2009, CURR OPIN MOL THER, V11, P421
[7]
Gastric adenocarcinoma - Review and considerations for future directions [J].
Dicken, BJ ;
Bigam, DL ;
Cass, C ;
Mackey, JR ;
Joy, AA ;
Hamilton, SM .
ANNALS OF SURGERY, 2005, 241 (01) :27-39
[8]
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis [J].
Dohi, T ;
Beltrami, E ;
Wall, NR ;
Plescia, J ;
Altieri, DC .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (08) :1117-1127
[9]
Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax [J].
Garg, H. ;
Salcedo, R. ;
Trinchieri, G. ;
Blumenthal, R. .
CANCER GENE THERAPY, 2010, 17 (03) :155-163
[10]
Greco O, 2001, MOL CANCER THER, V1, P151